Sponsors are asking for data you still deliver by hand.
The FDA launched Real-Time Clinical Trials in April 2026, and ICH E6(R3) is in force. Sponsors will expect their CRO to have an answer.
A trial with five labs has five manuals, each with its own units and ranges, checked against the protocol by a scientist.
Under E6(R3) the site owns its records and chooses its systems. A 40-site trial is 40 setups with no overlap.
E6(R3) requires showing where every value came from and a published data-flow diagram. Nightingale produces both.
The regulatory clock sponsors are asking about
What you would be delivering.
A Phase III study generates around 97,000 queries, and more than half change no data at all 6. Nightingale stops them being created.
Protocol, lab and pharmacy manuals, consent, questionnaires and eCRF guidelines reconciled before enrollment.
Devices, patient apps, labs, paper and other systems, into whichever database the study uses.
Delivered in the format regulators expect, with a record of where every value came from and what was done to it.
Fixed rules decide every value, so the same input always gives the same result and anyone can check the rule.
Check the rulebook
Every study document vs each other and vs FDA, EMA, ICH. Conflicts flagged before enrollment.
Example
Protocol in kilometers, lab manual in miles. Flagged on day one, not month four.Inventory what exists
Records, prior labs, device history and paper, filtered to what counts.
Example
Two years of blood pressure already in the chart get structured and counted.Find the gap
What the sponsor needs minus what exists = what to collect.
Example
ECGs needed at weeks 4, 12, 24; records cover week 4 for a third of patients.Run the data
Map, convert, check, deliver into the EDC. No retyping.
Example
Watch reports 10 miles; 16.09 km lands in the right field, with the conversion recorded.Watch it daily
Gap re-checked on live data; early warning when an endpoint is at risk.
Example
Site 17's ECG timestamps drift 40 minutes. Flagged in week 3, not at lock.Prove every step
An audit trail for every data point, created or verified.
Example
Where did this glucose value come from? One click: device, time, conversion, reviewer.A source link proves a number is real. It does not prove it is right. Every value carries two things: where it came from, and the rule that produced it, checked against the protocol, the lab manual and the consent form before the first patient. When one of those documents changes, the values it governs are flagged for re-review rather than quietly inheriting the old definition.
Your capability. Our engineers.
A partner model, not a vendor contract. You own the client relationship and the pricing.
Your brand, not ours.
Sponsors see your capability, not a third-party logo. That is the point of doing this with us rather than buying a tool.
You keep the spread.
We quote a partner rate. You price the work at what it is worth to your client and keep the difference.
No FTEs, no platform fee.
Nightingale becomes the data layer you propose by default, with a minimum number of studies a year.
Who does what
- Sponsor relationship and study management
- Pricing and the proposal
- Your brand on the capability
- Rulebook check before enrollment
- Source connections and the pipeline
- Daily monitoring and the audit trail
- Forward-deployed engineers, scoped per protocol
- No new logins or tools
- Never a customer
- Re-keying workload goes down
Estimate the hours you get back.
Margin on both sides: fewer delivery hours on work you already bill, plus the spread between our partner rate and the price you set.
Data-management hours freed
Based on 70% of that work removed, the figure we measure with you on the first study.
Capacity for more studies, or margin on work you already bill
at 2,080 hours per FTE year
Defaults: ~12 hours a week per data manager on query and reconciliation work 9, ~$70 an hour 8, and 70% of manual work removed, our design target, measured against your baseline on the first study. Your spread on the partner rate comes on top.
Where the margin comes from
Illustrative proportions; your rate card sets the real numbers.
Forward-deployed engineers stand it up inside your operation, scoped per protocol to your timeline.
How many trials this applies to.
The trials this applies to, counted from the public registry rather than estimated from market reports.
Interventional trials of any phase, and device, diagnostic or digital-health studies, that collect data from more than one electronic source and report into a study database.
Studies with wearables, home visits, several labs or many sites, where reconciling sources by hand is the bottleneck.
Registry-only and observational studies with a single data source, where there is little to reconcile.
The trial pool keeps growing: registrations have risen every year since the registry opened in 2000 13. Counts are from public registry data; the in-scope figure is our estimate, not a registry statistic.
Bids you cannot defend today.
A capability on your side of the table, not a line item on your cost sheet.
When a sponsor asks how you deliver data as it happens, the answer is that nothing is typed in by hand.
Bid on studies using wearables, home visits and constant reporting, without building the systems yourself.
Based on participants, number of data sources and study length, all known at bid time.
Fewer delivery hours on work you already bill, plus the spread on the partner rate.
Questions sponsors put in your bid, answered
Why partner rather than build it in-house.
You get the capability on your side of the table without an engineering program of your own.
Building a tool that removes those hours competes with your own revenue. Partnering lets you keep the margin instead.
Sponsors run Medidata, Veeva, Oracle and others. The layer works with whichever one a study already uses.
Every trial teaches the system another lab format and device export, across sponsors. One CRO's studies cannot rebuild it.
Deployment drops from about four weeks on a first trial to about two on the next, starting from existing connectors.
What building it costs, on conservative numbers
Figures use public salary benchmarks and conservative effort: four engineers at $180K fully loaded, eleven months to a working version, five person-months of computer system validation, eight source types maintained, eighty person-days of data work per study, four studies a year, 220 working days a year. They exclude hiring time, protocol amendments, scope creep and the revenue at risk during the build, all of which push a build higher. Run at high enough volume, an in-house build can be cheaper in cash once it works; we will run the numbers with you either way.
What changes on a large Phase III.
The work your data-management team does by hand today, and what it looks like with the layer in place.
Illustrative: a 2,000-patient, 120-site, 14-source, three-year Phase III modeled from the published figures in the appendix. Design targets under validation, not measured averages.
From a first call to your portfolio.
A 30-minute call on your active trials, sponsor mix, and where data work is costing you today.
A complimentary hands-on review of one active trial: sources, cleanup steps, and EDC targets.
Written findings, partner rate card, white-label terms, and the annual study minimum that sets default status.
Baseline a comparable trial, run Nightingale alongside on one study, then compare the number of queries, how many are resolved first time, and the lock date before you commit.
Live, audited, and adding a small number of partners.
EmpowerMBC at Emory University, a Gilead-funded oncology study under Dr. Lauren McCullough, is our flagship live deployment and the reference we will put on a call. Our GxP vendor audit is complete; SOC 2 Type II is in progress. We will baseline on your study before we claim anything.
$340K contracted across signed agreements, the majority through a CRO partner rather than direct: Emory University plus two medical-device trials via Thinq CRO. Harvard iLab company, 11 signed channel partners, and onboarding into the Georgia CTSA Program.
The questions CROs ask.
The layer has to be indifferent to every EDC, and a database vendor cannot be indifferent to itself. The sources also belong to each site: a 40-site trial is 40 different setups, which no single vendor standardizes.
Yours. The layer is white-labeled by default and delivered as your capability, with our forward-deployed engineers working inside your operation.
A minimum number of studies a year sets default status. There is no FTE commitment and no platform fee. The partner rate card and white-label terms come in writing at step three.
Run it in parallel. We baseline a comparable trial you have run, deploy alongside on one study, and compare the number of queries, how many are resolved first time, and the lock date before you commit the portfolio.
Emory already has. The GxP vendor audit is complete, Part 11 alignment is in place, SOC 2 Type II is in progress, and storage stays with the sponsor.
A source link proves a value is real. It does not prove it was collected under the definition the analysis assumes. We check the study's documents against each other before enrollment, record which rule produced each value, and flag values for re-review when a document, a definition or a data version changes.
It removes manual re-keying, reconciliation and queries that change nothing. How you use the freed hours, on more studies or as margin, is your call.
Any EDC a study already runs, including Medidata, Veeva and Oracle, and data from devices, patient apps, labs, paper and other systems.
Start with a portfolio review.
Thirty minutes on your active trials, sponsor mix, and where data work is costing you today.
Pick a time that works for you. We will come prepared to talk through your portfolio and whether a partnership fits.
Book a portfolio reviewWhat happens next
A 30-minute call on your active trials and sponsor mix.
A complimentary hands-on review of one active trial.
Written findings, partner rate card and white-label terms.
Sources behind every figure.
Show all 20 sources
- Tufts Center for the Study of Drug Development (2021): Phase III protocols average 3.6 million data points, three times the volume of ten years earlier.
- Marra C. et al. (2020), npj Digital Medicine: connected digital products in trials grew ~34% per year, 2000-2017.
- Tufts CSDD, eClinical Landscape Study: 257 organizations; median 8.1 days from patient visit to EDC entry.
- Advarra, Study Activation Survey 2023: N>500 sites; ~69% use six or more sponsor systems.
- Garza M. et al. (2026): manual transcription error rate 8.23%; integrated capture showed no detected transcription errors.
- Stokman P. et al. (2021), Journal of the Society for Clinical Data Management 1(1), DOI 10.47912/jscdm.20: 20 Phase III studies, 1,939,606 queries; ~96,980 per study; 42% resulted in a data change.
- Smith Z., DiMasi J., Getz K. (2024), Therapeutic Innovation & Regulatory Science 58(5):855-862: direct cost of trial delay $55,716/day; opportunity cost on the order of $500,000/day.
- Salary.com, US Clinical Data Manager compensation, September 2026: average $144,625, ~$70/hour.
- Vendor-sponsored industry survey, n=88: ~12 hours/week per data manager per study on query and reconciliation work. Indicative.
- Moore T. et al. (2018), JAMA Internal Medicine: median cost per patient in pivotal trials ~$41,117. Per-source and fixed-cost components are estimates.
- IQVIA Institute, Global Use of Medicines: global medicine spending ~$1.6T. Medical device market ~$600B (industry estimate). WHO: global health spending ~$10T.
- Evaluate Pharma / IFPMA: pharmaceutical R&D ~$300B per year; medtech and digital-health R&D ~$50B (estimate). IQVIA Technologies, Veeva and Medidata combined revenue ~$10B.
- ClinicalTrials.gov: more than 35,000 new studies registered per year. The ~20,000 addressable interventional figure is an estimate.
- ClinicalTrials.gov sponsor records: Pfizer ~423 tracked / 251 active; Eli Lilly ~333. Order-of-magnitude proxy.
- ICH E6(R3): §3.16.1(c), §3.16.2(c), §2.12. Step 4 6 Jan 2025; EU 23 Jul 2025; FDA 9 Sep 2025; Annex 2 adopted 3 Jun 2026, effective 15 Jan 2027.
- FDA Digital Health Technologies guidance (Dec 2023); FDA Part 11 Q&A (Oct 2024); FDA and EMA AI principles (Jan 2026); FDA Real-Time Clinical Trials (28 Apr 2026); HHS and ARPA-H SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), solicitation ARPA-H-SOL-26-164 (30 Sep 2026).
- Disclosed transactions: Change Healthcare/Optum $13B; Datavant/Ciox ~$7B; Komodo Health $3.3B; Flatiron Health/Roche $1.9B; Truveta >$1B; Tempus AI market capitalization ~$10.6B.
- Public revenue multiples: Snowflake at IPO >100× trailing; Palantir ~80× (2025); Cloudflare ~35× (2025); Databricks ~27× (private, 2025).
- Private comparables: a September 2026 software seed round at $7M on $100M post-money with ~$500K lifetime revenue; a clinical-trial software company that raised under $400K in total and sold for roughly half a billion dollars. Details available on request.
- FDA, Considerations for the Design and Conduct of Externally Controlled Trials, draft guidance, February 2023. EMA, qualification opinion on prognostic covariate adjustment using digital twins (PROCOVA), September 2022.
- Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019, JAMA Network Open (2020): of 245,999 interventional studies, 70,329 (28.5%) were industry-sponsored.